Publications Office of the EU
Open House Biologics Discount Contracts 2025-01 - Infliximab - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Open House Biologics Discount Contracts 2025-01 - Infliximab Text automatically translated in your browsing language Automatically translated

Overview
  • Published
    13/02/2025
  • Today
    27/03/2025
  • Deadline
    31/03/2027
  • Opening of tenders
    31/03/2027
Status
Published
Type of contract
Supplies
Subject for Renewal
No
Buyer
Techniker Krankenkasse
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE600 Hamburg
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Number of lots
2
Procedure details
Tender reference number
OB-2025-01
Description

The participating funds pursue the objective of concluding rebate agreements with all suitable pharmaceutical companies in accordance with § 130a(8) SGB V on the active substance infliximab (for the division into two lots, see below). The contract is concluded within the framework of the open-house biologics procedure of the participating funds: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurance companies do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 24 months starting from 01.04.2025. The contract ends at the latest on 31.03.2027, regardless of the date of conclusion of the contract. It is possible to join this open-house biologics procedure at any time within the term of the contract. Due to the existence of industrial property rights with regard to the active substance or combination of active substances that are the subject of these proceedings, in lot 1 (infliximab (form of administration for subcutaneous injection)), the participation and contractual documents are only made available to those pharmaceutical entrepreneurs who offer/place on the market medicinal products containing the active substance or combination of active substances that are the subject of these proceedings or who credibly demonstrate to TK that they want to offer/place on the market such medicinal products within the term of the contract. All further information can be found in the participation and contract documents. Text automatically translated in your browsing language Automatically translated

Submission Method
Not available
Tenders may be submitted
Electronic submission: eu.europa.publications.PublicProcurement.electronic.submission.not-allowed
tdf-non-av
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
31/03/2027 23:59
Buyers
Handelskrankenkasse (hkk)
HEK - Hanseatische Krankenkasse
DAK-Gesundheit (DAK-G)
Kaufmännische Krankenkasse (KKH)
Place of performance
DE Deutschland
DE600 Hamburg
CPV code

33600000 - Pharmaceutical products

Lots (2)
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.